Dominari Holdings Inc. — FY2023 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 31, 2023, and was signed April 1, 2024. Dominari is transitioning from biotechnology toward financial services, including wealth management, investment banking, sales and trading, and asset management. It completed its acquisition of broker-dealer and investment adviser Fieldpoint Private Securities, renamed Dominari Securities, on March 27, 2023. The company is winding down its legacy biotechnology pipeline.
Financial performance and position
| Metric | FY2023 / Dec. 31, 2023 | FY2022 / Dec. 31, 2022 |
|---|---|---|
| Revenue | $2.039 million | $0 |
| Operating loss | $21.796 million | $14.346 million |
| Net loss | $22.882 million | $22.107 million |
| Net loss per share, basic and diluted | $4.38 | $4.91 |
| Cash used in operating activities | $22.232 million | $10.597 million |
| Cash used in investing activities | $7.170 million | $14.598 million |
| Cash used in financing activities | $0.939 million | $7.193 million |
| Cash and cash equivalents | $2.833 million | $33.174 million |
| Total assets | $57.558 million | $76.236 million |
| Total liabilities | $4.635 million | $2.469 million |
| Stockholders’ equity | $52.923 million | $73.767 million |
Revenue in 2023 comprised underwriting ($594,000), commissions ($1.096 million), advisory fees ($209,000), and other revenue ($140,000). The filing does not provide a clear consolidated gross margin. The company reported $13.547 million of marketable securities, $7.687 million of deposits with its clearing broker, $24.150 million of long-term investments, and $4.306 million of notes receivable at fair value. Management reported working capital of approximately $26.5 million.
Total lease liabilities were $3.449 million, including $421,000 current and $3.028 million long-term; the filing reports no other contractual obligations. Dominari Securities had approximately $4.9 million of net capital, about $4.7 million above its $0.2 million regulatory minimum.
Material changes versus FY2022
- Revenue began with the financial-services business acquired in 2023; the prior-year filing reported no revenue.
- Operating loss widened by approximately $7.45 million. General and administrative expense rose about $12.2 million, including approximately $9.5 million of increased compensation expense and costs to establish and operate Dominari Financial and Dominari Securities. Research and development expense fell sharply as the company shifted away from biotechnology.
- Net loss increased by approximately $775,000 despite improvement in other expenses, which narrowed from $7.761 million to $1.086 million. The 2023 result included a $3.248 million unrealized loss on a note receivable, partly offset by a $630,000 gain on marketable securities and a $780,000 gain from changes in investment fair value.
- Operating cash use more than doubled, while year-end cash fell by approximately $30.3 million. Investing cash use declined, reflecting investment purchases and sales, the FPS acquisition, and note collections.
- Accumulated deficit increased to $208.763 million from $185.881 million. The company reported an approximate $22.9 million net loss for 2023 and stated it has continuing operating losses.
Outlook, risks, contingencies, and unusual items
- Management said cash, cash equivalents, marketable securities, and anticipated operating cash flows are expected to fund working-capital and capital-expenditure needs for at least 12 months. It also said additional capital may be needed sooner if cash flows, expenses, or business plans differ from expectations. No numerical revenue or earnings guidance was provided.
- Management identified a material weakness in internal control over financial reporting related to the design and maintenance of fair-value reporting for certain notes receivable. Disclosure controls and procedures were also concluded to be ineffective. Management described plans to enhance controls and consult experienced third-party professionals; remediation is not established in the filing.
- Valuation of $24.15 million of investments without readily determinable fair values was identified by the auditor as a critical audit matter, involving significant management judgment. The notes receivable are also Level 3 fair-value assets; the filing recorded a $3.248 million unrealized loss on notes in 2023.
- A March 2024 petition was filed against Dominari Securities relating to affiliates of new registered representatives. The company disputes the claim; the potential loss cannot be reasonably estimated, and no loss contingency was recorded.
- Risks include early-stage financial-services operations, ongoing losses and cash needs, dependence on market activity and key personnel, extensive securities regulation, competition, fair-value estimation, cybersecurity and operational exposures, and possible Nasdaq delisting. The company reported no material business impact from cybersecurity threats to date, while warning of future exposure.
- Compensation and dilution warrant attention: the filing reports fully vested 2023 restricted-stock grants to Soo Yu and other recipients, and 2023 stock-based compensation expense of approximately $2.977 million. The company also repurchased 236,630 shares for approximately $939,000 in 2023.
Most important facts for investors to verify
- Whether financial-services revenue and client assets grow enough to reduce operating losses and cash burn, and whether management’s 12-month liquidity assessment remains supportable.
- How the company substantiates the carrying values and collectability of its Level 3 notes receivable and $24.15 million investment portfolio.
- Whether the fair-value control material weakness is remediated and whether disclosure controls and internal financial reporting controls become effective.
- The status, potential financial impact, and any developments in the March 2024 legal petition.
- Future capital needs, potential equity dilution, regulatory capital headroom, and the effects of share-based awards and executive compensation arrangements.